Skip to main content

What about side effects?

Key facts

  • After having a vaccination, some adolescents may feel a bit unwell for a few days and then get better. 

  • Serious side effects are very rare. When they do occur, it is important for adolescents to get the support they need from a healthcare professional or at a hospital.

Last updated on 13 August 2025.
Will my adolescent have a reaction to the vaccines?

Some adolescents might feel a bit unwell for a day or two after they get their vaccinations. Common reactions are generally mild and go away on their own after a few days. These reactions can include local swelling, redness or pain at the injection site, mild fever, headache or tiredness.

Can the vaccines have any serious side effects, even if they are rare?

Serious side effects are very rare, but they can happen, and some parents want to know more about them before they vaccinate their adolescent.

Anaphylaxis is a severe allergic reaction to one or more vaccine components. About 0.0001% (1 in 1,000,000) of people have this reaction following vaccination.1 Anaphylaxis usually happens within 15 minutes of receiving a vaccine, most likely before your adolescent leaves the school or clinic setting, and can be treated with an injection of adrenaline. People who have this reaction usually recover quickly and don’t experience any long-term effects.1

Less than 2% of adolescents can experience a large (extensive) amount of limb or arm swelling after receiving booster doses of the combination vaccine that protects against whooping cough (pertussis), diphtheria and tetanus. This reaction usually happens within 48 hours, lasts for 1–7 days and then resolves completely.2

Around 0.5–1 in 100,000 of tetanus toxoid-containing vaccine doses given in adults are linked to a swelling or inflammation of a nerve in the arm (brachial neuritis), which causes weakness or numbness.3,4 The seriousness and how long this reaction lasts varies on a case-by-case basis.

Guillain-Barré syndrome (GBS) is a rare disorder where a person’s immune system damages their peripheral nerve cells. It usually begins with tingling and weakness in the legs and can spread to the arms and face, leading to muscle weakness, loss of sensation and problems swallowing or breathing. While many people recover fully, others may continue to experience persistent symptoms.5,6 GBS occurs at a very low rate of up to 1 in 1,000,000 doses of influenza (flu) vaccine (0.0001%).7 People infected with the flu are more likely to get GBS than people who get the flu vaccine.8,9

One study from France showed the possibility of a very small increased risk (approximately 1 in 100,000 girls vaccinated) of a person developing GBS after receiving a human papillomavirus (HPV) vaccine.10 However, other large studies that collectively included more than 10 million people showed that GBS is very rare and the evidence for it being associated with HPV vaccination is weak.11,12,13,14

Very rarely (0.001–0.002% of doses, or 1–2 in every 100,000), people receiving a vaccine that protects against COVID-19 can experience a swelling or inflammation of the heart muscle (myocarditis) or the lining of the heart (pericarditis).15

Do the benefits of vaccination outweigh the risk of a vaccine side effect?

Yes. When vaccination is recommended for your adolescent, the benefits of vaccination outweigh the risk of a vaccine side effect. While rare, some of these infectious diseases can have life-long effects on the adolescents who catch them. Some of these diseases can even be fatal.

Compared to catching a vaccine preventable disease, the side effects of vaccination are usually mild (like getting a sore arm or feeling tired) and go away quickly. Most of the common reactions will last between 12 and 24 hours and then get better.

Please note: In SKAI Adolescent, the phrase ‘your adolescent’ refers to all guardian relationships where health decisions for an adolescent fall under your responsibility.

Drafts of this page were reviewed by members of our Consumer Advisory Group.


  1. McNeil MM, Weintraub ES, Duffy J et al. Risk of anaphylaxis after vaccination in children and adults. Journal of Allergy and Clinical Immunology 2016;137:868-78
  2. Mertsola J, Van Der Meeren O, He Q et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clinical Infectious Diseases2010;51:656-62
  3. Hamati-Haddad A & Fenichel GM. Brachial neuritis following routine childhood immunization for diphtheria, tetanus, and pertussis (DTP): report of two cases and review of the literature. Pediatrics 1997;99:602-3
  4. Institute of Medicine. Stratton KR, Howe CJ, Johnston RB, Jr. (Eds). Adverse events associated with childhood vaccines: evidence bearing on causality. Washington DC: National Academy Press; 1994. Available from https://pubmed.ncbi.nlm.nih.gov/25144097/
  5. Estublier B, Colineaux H, Arnaud C et al. Long‐term outcomes of paediatric Guillain–Barré syndrome. Developmental Medicine & Child Neurology 2024;66:176-86
  6. National Institute of Neurological Disorders and Stroke. Guillain-Barre syndrome. November 2024. Available from https://www.ninds.nih.gov/health-information/disorders/guillain-barre-syndrome
  7. Nelson KE. Invited commentary: influenza vaccine and Guillain-Barré syndrome – is there a risk? American Journal of Epidemiology 2012;175:1129-32
  8. Vellozzi C, Iqbal S & Broder K. Guillain-Barre syndrome, influenza and influenza vaccination: the epidemiologic evidence. Clinical Infectious Diseases 2014;58:1149-55
  9. Kwong JC, Vasa PP, Campitelli MA et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. The Lancet Infectious Diseases2013;13:769-76
  10. Miranda S, Chaignot C, Collin C et al. Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France. Vaccine 2017;35:4761-68
  11. Boender TS, Bartmeyer B, Coole L et al. Risk of Guillain-Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 January 2000 to 4 April 2020. Eurosurveillance 2022;27
  12. Andrews N, Stowe J & Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine 2017;35:1729-32
  13. Gee J, Sukumaran L & Weintraub E. Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink. Vaccine 2017;35:5756-58
  14. Deceuninck G, Sauvageau C, Gilca V et al. Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine. Expert Review of Vaccines 2018;17:99-102
  15. Hause AM, Baggs J, Marquez P et al. Safety monitoring of COVID-19 vaccine booster doses among persons aged 12–17 years – United States, December 9, 2021–February 20, 2022. Morbidity and Mortality Weekly Report 2022;71:347